Vanguard Global Advisers’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCVX
KCM
Vanguard Global Advisers's PCVX Position: Q3 2026 in Review
Vanguard Global Advisers increased its Vaxcyte (PCVX) stake by 15% in Q3 2026, buying an estimated $430K and bringing the position to 57,157 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #969.
Vanguard Global Advisers first reported a position in PCVX in Q1 2026 and has held it in 3 quarters since. 297 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.
- Vanguard Global Advisers held 57,157 shares of Vaxcyte worth $3.25M as of Q3 2026.
- Vanguard Global Advisers bought 7,370 Vaxcyte shares in Q3 2026, an estimated $430K.
- Vaxcyte made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #969 holding.
- Vanguard Global Advisers first reported a position in Vaxcyte in Q1 2026 and has held it in 3 quarters since.
- 297 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.